Contents
Novo Integrated Sciences $NVOS sales are forecast to be up north of 300%! Here are the exciting details of what is going on with the company.
Novo Integrated Sciences Announces Preliminary Revenue Range for Fiscal 2022 Third Quarter
On July 11, 2022, Novo Integrated Sciences, Inc. (NASDAQ: NVOS), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today announced that its preliminary unaudited revenue for the third quarter of fiscal 2022 is expected to be in the range of $13.4 million to $13.9 million, an increase of approximately 367% to 384%, as compared to the second quarter of fiscal year 2022, and an increase of approximately 463% to 484%, as compared to the third quarter of fiscal 2021. The Company’s strong revenue performance in the third quarter was driven primarily by an increase in both proprietary and outsourced product sales.
Robert Mattacchione, Novo’s CEO and Board Chairman, stated, “We are extremely pleased with the revenue increase for the quarter. The addition of product development and sales to our corporate bandwidth is proving to be a successful strategy toward accelerating the Company’s growth. We believe that subsequent quarters will illustrate continued market penetration for our expanding line of product solutions. The conversion of patients to consumers and consumers to patients, combined with continuing commercialization of our proprietary technology and product solutions, is expected to have an ongoing positive impact on the growth of the Company’s holistic healthcare solutions globally.”
Novo Integrated Sciences Inc. is a provider of multi-dimensional primary healthcare services and products principally in Canada and the U.S. It deliver or intend to deliver, multidisciplinary primary health care related services and products through the integration of medical technology, advanced therapeutics and rehabilitative science, through its subsidiaries. Novo Integrated Sciences Inc. is based in Bellevue, Washington.